In vitro antimicrobial activity of a new antibiotic, MDL 62,879 (GE2270 A).
MDL 62,879 (GE2270 A) is a new peptide antibiotic that inhibits protein synthesis through an interaction with elongation factor Tu. MDL 62,879 was very active against gram-positive clinical isolates, particularly staphylococci and enterococci, for which MICs for 90% of isolates were < or = 0.13 micrograms/ml. It was equally active against isolates resistant to beta-lactams, erythromycin, gentamicin, and glycopeptides. It also had activity against Mycobacterium tuberculosis. MDL 62,879 had moderate bactericidal activity against staphylococci.
Lepetit Research Center, Marion Merrell Dow Research Institute, Gerenzano, Varese, Italy.
B P
BP
Goldstein
M
M
Berti
F
F
Ripamonti
A
A
Resconi
R
R
Scotti
M
M
Denaro
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D016983:Enterococcus / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology*; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D013844:Thiazoles / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D010455:Peptides; D010456:Peptides, Cyclic; D013844:Thiazoles; C068122:GE 2270 A